Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Look Back At 2010: In Search Of New Biopharma Models

Executive Summary

2010 was a year of transition, filled with the exploration of new industry models. Health care reform hinted at short-term pain and long-term gain while investment, R&D and commercial challenges combined with a heightened sense of industry desperation to bring out biopharma's creative side. But as with any experiment, there is ample risk of failure.

Related Content

Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Putting The Pieces Together Again: GSK Creates End-To-End Business Units
As Pfizer And UCSF Tighten Ties, More Deals With Academia Could Follow
Reata's $450 Million Up-Front Haul Sets A Record But Remains An Outlier
Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts
With Pharma Ready to Pare Portfolios, Project Financing Funds Make Their Pitches
Health Care Reform: For Biopharmas There Is Much To Like
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Biopharma Trends: Nowhere To Go But Up
Pfizer/Angiosyn: Building Biotechs for Device-style Early M&A


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts